# Lebrikizumab for adolescent atopic dermatitis: 24-week real-world outcomes from the Czech BIOREP registry

**Authors:** Filip Rob, Blanka Pinková, Petra Gkalpakioti, Jiřina Bartoňová, Jiří Horažďovský, Jan Říčař, Jana Třešňák Hercogová, Kristýna Sokolová

PMC · DOI: 10.1016/j.jdin.2026.01.009 · JAAD International · 2026-02-01

## Full-text entities

- **Diseases:** atopic dermatitis (MESH:D003876)
- **Chemicals:** Lebrikizumab (MESH:C561806)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12997194/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12997194/full.md

## References

5 references — full list in the complete paper: https://tomesphere.com/paper/PMC12997194/full.md

---
Source: https://tomesphere.com/paper/PMC12997194